[go: up one dir, main page]

Blacker et al., 2007 - Google Patents

How regenerating lymphatics function: lessons from lizard tails

Blacker et al., 2007

View PDF @Full View
Document ID
2044057253263942693
Author
Blacker H
Tsopelas C
Orgeig S
Daniels C
Chatterton B
Publication year
Publication venue
The Anatomical Record: Advances in Integrative Anatomy and Evolutionary Biology: Advances in Integrative Anatomy and Evolutionary Biology

External Links

Snippet

Rational treatment of lymphoedema may be improved in the future with a better understanding of the physiological processes involved in the regeneration of new lymphatic vessels (lymphangiogenesis). Many lizard species undergo tail autotomy as a predator …
Continue reading at anatomypubs.onlinelibrary.wiley.com (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells

Similar Documents

Publication Publication Date Title
Gray et al. Regression of liver metastases following treatment with yttrium-90 microspheres.
Becerra et al. Distribution of injected technetium99m‐labeled mesenchymal stem cells in horses with naturally occurring tendinopathy
Linden et al. Serotonin availability is increased in mucosa of guinea pigs with TNBS-induced colitis
Mendichovszky et al. Imaging hypoxia in gliomas
Toumi et al. The role of neutrophils in injury and repair following muscle stretch
Korsen et al. Delta-like ligand 3–targeted radioimmunotherapy for neuroendocrine prostate cancer
Hassan et al. Feline mammary cancer: Novel nude mouse model and molecular characterization of invasion and metastasis genes
McDougall et al. Thyroid stunning: fact or fiction?
Filice et al. Radiolabeled somatostatin analogues therapy in advanced neuroendocrine tumors: a single centre experience
Jawad et al. Effects of sclerostin antibody on healing of a non‐critical size femoral bone defect
Du et al. Intra-arterial delivery of human bone marrow mesenchymal stem cells is a safe and effective way to treat cerebral ischemia in rats
Rosa-Caldwell et al. Altering aspects of mitochondrial quality to improve musculoskeletal outcomes in disuse atrophy
Bao et al. Optimization of early response monitoring and prediction of cancer antiangiogenesis therapy via noninvasive PET molecular imaging strategies of multifactorial bioparameters
Chang et al. PEGylated liposome-encapsulated rhenium-188 radiopharmaceutical inhibits proliferation and epithelial–mesenchymal transition of human head and neck cancer cells in vivo with repeated therapy
AU2017376822B2 (en) Radiolabelled material for targeted administration
Ilhan et al. Nephroprotective effects of enalapril after [177Lu]-DOTATATE therapy using serial renal scintigraphies in a murine model of radiation-induced nephropathy
Cai et al. 90Y-labeled gold nanoparticle depot (NPD) combined with anti-PD-L1 antibodies strongly inhibits the growth of 4T1 tumors in immunocompetent mice and induces an abscopal effect on a distant non-irradiated tumor
Unekawa et al. Sustained decrease and remarkable increase in red blood cell velocity in intraparenchymal capillaries associated with potassium‐induced cortical spreading depression
de Castro Cunha et al. Canine squamous cell carcinoma: Electrochemotherapy association with surgery and correlation with overall survival
Blacker et al. How regenerating lymphatics function: lessons from lizard tails
Fournier et al. MR monitoring of cyclooxygenase-2 inhibition of angiogenesis in a human breast cancer model in rats
Hahn et al. Dynamics of human serotonin synthesis differentially link to reward anticipation and feedback
Becker et al. Ultrastructural assessment of myocardial necrosis occurring during ischemia and 3-h reperfusion in the dog
Tanaka et al. Treatment of hepatocellular carcinoma with autologous platelets encapsulating sorafenib or lenvatinib: A novel therapy exploiting tumor‐platelet interactions
Anderl et al. Retention and biodistribution of microspheres injected into ischemic myocardium